CRW H2 2026 14:30 UTC Results Presentation

Page 1

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 1 © 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. Craneware plc: Final Results FY26 Keith Neilson, CEO and Co-founder, Craig Preston, CFO

Page 2

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 2 Agenda 01 Introduction & Overview of the Period 02 03 04 Cyber Security Incident Update Financial Review 340B Market Update & Our Response 05 Growth Strategy: A consistent focus on our strengths 06 Outlook

Page 3

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 3 We partner with healthcare providers across the US to improve and sustain their operational and financial performance. Our innovative software solutions elevate healthcare revenue intelligence, decision support, and 340B performance. Financially resilient $185m ARR, NRR of 100% Average relationship of top 10 customers is 21 years c.90% of revenue is recurring Commitment to 30%+ EBITDA margins Strong cash generation

Page 4

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 4 Introduction FY26 impacted by 340B headwinds FY26 Performance review and outlook Solid foundation of recurring revenue Confident in FY28 growth • Slow down in 340B transaction revenues in H2 as unilateral manufacturer restrictions kicked in. • Resilient ARR from recurring revenue sources: $185m, NRR 100%. • Healthy customer retention rates of above 90% on all our measures. • Strong EBITDA performance & cash generation. • Further certainty within 340B market anticipated through FY27 at both State and Federal level. • Prior investment into our 340B offering means we can support customers in meeting both current and upcoming models - placing us ahead of the competition. • Revenue integrity product launches will increase cross and upsell opportunity. • Intention to achieve +30% EBITDA margin in the medium term. • Cyber security incident now entered remediation phase. • Rebasing our revenue expectations to level of recurring revenue, c. $185m, providing certainty to all stakeholders. • Comprehensive review of cost base initiated to align business structure with revenue. • Microsoft partnership represents AI and win accelerator.

Page 5

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 5 Introduction What happened Cyber security incident update Current status • Incident contained: In July 2026, the Group identified and promptly contained unauthorised access to part of its data environment. • Rapid response: The established response plan was activated, supported by external cyber security and forensic specialists. • Operations unaffected: core operations and customer services continued without disruption, with no residual indicators of compromise identified. • Data impact: A subset of data was viewed and exfiltrated; while much was non-sensitive or publicly available, certain employee, customer and partner records were affected. • Moving into Remediation phase: The Group continues to assess the scope, notify affected parties and engage with regulators and law enforcement. • Financial treatment: The incident is a non-adjusting post-balance-sheet event, with subsequent costs recognised as incurred; the ultimate financial impact remains uncertain. • Recurring revenues, balance sheet and cash generation provide confidence in our resilience.

Page 6

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 6 New Hospitals, 10% Existing Hospitals on Renewal, 8% Existing Hospitals not on Renewal, 82% A robust sales performance Continued expansion sales and competitive wins FY26 - Annual Value of 'new' Sales Example H2 new customer wins: • 3-year 340B Program modernisation contract with an independent regional health system replacing a competitor. • 5-year Revenue Integrity contract, displacing a competitor, at a large academic health system, following the acquisition of a Craneware customer by the group. • 3-year Revenue Integrity and Pricing Optimization contract, with a regional community health system, supporting pricing strategy, chargemaster governance and a payer audit management. • 2-year Medication margin improvement contract with a leading oncology health system, creating a meaningful land & expand opportunity. Example H2 existing customer expansions: • 4-year Chargemaster and Revenue Integrity contract with large multi-hospital health system requiring a unified solution following a consolidation of legacy facilities. • 5-year Revenue Cycle contract with a regional community health system customer, following recent revenue integrity win. • Revenue integrity and Pricing strategy professional services contract with an existing large academic health system customer. Increase in new hospitals secured (10% v 2% FY25), providing future expansion opportunity. Customer retention >90% on all our metrics.

Page 7

Page 8

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 8 FY26 Financial KPIs & FY27 Reset ARR Operating Cash Conversion Total Bank Debt Revenue Adj. EBITDA Adj. EPS (cents) (FY25: $205.7m) $206.0m (FY25: $65.3m) $67.1m (FY25: 116.1c) 116.8c$185m (FY25: $184m) 98% (FY25: 94%) (FY25: $27.7m) $43.5m • FY26 revenue performance below our expectations due to 340B headwinds: underlying sales performance in line with prior year, healthy margin performance and cash conversion. • Our ARR provides a strong foundation for the business: • No one customer accounts for more than 8% of ARR. • The Group’s top 10 customers account for less than 30% of ARR, with an average length of customer contracting relationship of 21 years. • Implemented comprehensive review of costs to align business structure with revenue. • Capital allocation plans – no change to approach, continue to see investment in innovation as the foundation for our ability to address a substantial market opportunity.

Page 9

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 9 FY26 Review: Revenue and earnings ─ Revenue steady at $206.0m. (FY25: $205.7m) ─ Adj EBITDA increased 3% to $67.1m. (FY25: $65.3m) ─ Adj. basic EPS of 116.8 cents per share. (FY25: 116.1 cents) 165.5 174.0 189.3 205.7 206.0 $0 $50 $100 $150 $200 $250 FY22 FY23 FY24 FY25 FY26 Revenue (millions) 51.8 54.9 58.3 65.3 67.1 $0 $20 $40 $60 $80 FY22 FY23 FY24 FY25 FY26 Adj. EBITDA (millions) 89.0 87.0 94.8 116.1 116.8 0 20 40 60 80 100 120 140 FY22 FY23 FY24 FY25 FY26 Adj. Basic EPS (cents)

Page 10

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 10 • Continued strong cash management • Total dividend consistent with prior year of 32p Proposed final dividend of 17p per share. (FY25: 18.5p per share) 48.4 78.5 34.6 55.9 54.8 0 10 20 30 40 50 60 70 80 90 FY22 FY23 FY24 FY25 FY26 Cash ($m) 28.0 28.5 29.0 32.0 32.0 26.0 27.0 28.0 29.0 30.0 31.0 32.0 33.0 FY22 FY23 FY24 FY25 FY26 Dividend (pence/share) FY 2026 FY 2025 $000 $000 Cash generated from operations 55,435 69,595 Tax paid (12,541) (9,697) Net cash from operations 42,894 59,898 Purchase of plant and equipment and intangibles (17,359) (15,369) Interest received 1,236 1,384 Net cash from investing activities (16,123) (13,985) Dividend paid to company shareholders (15,742) (13,268) Drawdown of borrowings 20,138 - Repayment of borrowings (4,138) (8,000) Interest on borrowings (1,499) (2,176) Share buyback programme (25,080) - Other investing activities (1,555) (1,137) Net cash used in financing activities (27,876) (24,581) Net (decrease)/ increase in cash and cash equivalents (1,105) 21,332 Cash and cash equivalents at the end of the period 54,816 55,921 Cash at period end $54.8m (FY25: $55.9m). Further $56m (FY25: $72m) undrawn RCF available plus $100m accordion. Total Bank Debt of $43.5m (FY25: $27.7m). Cash conversion achieved 98% of EBITDA (FY25: 94%). FY26 Review: Cash & Dividend

Page 11

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 11 Annuity SaaS Model Driving contracted recurring revenue - 50 100 150 200 FY23 FY24 FY25 FY26 Software licensing Professional services - recurring Transactional revenue Other platform revenue Professional services - non-recurring ARR Contracted Recurring Revenue Non-Recurring SaaS Software Revenue Typical multi-year underlying contracts ─ High visibility of future revenues. Other recurring revenue ─ Transactional recurring revenue, with underlying long-term contracts. ─ Multi-year Professional Services, monthly revenue recognition. Professional services ─ Client training and Education. Platform Revenues ─ Leveraging Platform & Data. ─ Potential future ARR. $m Non-recurring revenue: $31m, 15% of total Recurring revenue: $175m, 85% of total

Page 12

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 12 Income Statement & EPS (FY25: 32%) Adj. EBITDA margin 33% Statutory PBT 7% $59.6m R&D Spend (FY25: $57.3m with $14.9m capitalised) $16.9m Capitalised (FY25: 18%) Eff Tax Rate 23% Headline Results Adj. EBITDA 3% Revenue Adj. Basic EPS* 1% * Adjusted EPS adjusted for exceptional costs and amortisation of acquired intangibles (tax adjusted) of $20,921k (FY25: $20,921k). Basic EPS 1% →0% EPS FY 2026 FY 2025 Basic ($ per share) 0.566 0.562 Adjusted Basic ($ per share) 1.168 1.161 Diluted ($ per share) 0.560 0.552 Adjusted Diluted ($ per share) 1.156 1.142

Page 13

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 13 Strong Balance Sheet FY 2026 FY 2025 $000 $000 ASSETS Non-Current Assets Property, plant and equipment 4,736 6,252 Intangible assets - goodwill 235,236 235,236 Intangible assets - acquired intangibles 103,564 124,485 Intangible assets – other 66,589 61,243 Trade and other receivables 2,582 3,752 Deferred tax - 499 412,707 431,467 Current Assets Trade and other receivables 54,224 63,672 Cash and cash equivalents 54,816 55,921 109,040 119,593 Total Assets 521,747 551,060 EQUITY AND LIABILITIES Non-Current liabilities Borrowings 43,495 - Leased properties > 1 year 2,155 3,011 Deferred tax 27,937 28,806 Other provision 209 574 73,796 32,391 Current Liabilities Borrowings - 27,740 Deferred Income 56,604 64,561 Amounts held on behalf of customers 50,910 61,323 Current tax liabilities 535 2,045 Trade and other payables 21,243 25,441 129,292 181,110 Total Liabilities 203,088 213,501 Equity Share capital 659 659 Share premium account - 97,204 Treasury shares (25,675) (2,804) Capital redemption reserve 9 9 Merger reserve - 186,981 Other reserves 11,685 11,242 Retained earnings 331,981 44,268 Total Equity 318,659 337,559 Total Equity and liabilities 521,747 551,060 Healthy Cash Reserves $54.8m (FY25: $55.9m) Banking Facilities $100m RCF - $56m available $100m Accordion available 2 years remaining + 2 further 1-year extensions available Shares in Issue 35,542,169 including 1,305,021 shares held in Treasury (FY25: 35,542,169 including 132,367 shares held in Treasury) Share premium account and merger reserve reclassification, providing additional distributable reserves to the Company.

Page 14

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 14 Capital Allocation Balancing the needs of our stakeholders Rapidly paid down debt, while in high- interest rate environment, gives >$156m of “fire power” for future decisions. • SaaS model underpinned by multi-year contracts, providing long-term revenue visibility. • Resetting our revenue expectations to the level of our ARR at $185m, providing certainty to all stakeholders. • Share Premium reduction exercise provides over $330m of distributable reserves, after $25m share buyback in FY26. Maintain R&D spend of approx. 25% of revenues, as we see considerable opportunity ahead. Dividend plus buybacks has seen $98.2m (c£75.9m*) returned to shareholders in 5 years. 0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 FY22 FY23 FY24 FY25 FY26 Returned to Shareholders (£m) H1 Div (£m) H2 Div (£m) Buybacks Paid (£m) 0 50 100 150 200 FY22 FY23 FY24 FY25 FY26 Available Bank Finance $m Drawn Undrawn Accordion 0 25 50 75 FY22 FY23 FY24 FY25 FY26 Invested in R&D $m Expensed Capitalised *return to shareholders calculated at the applicable year balance sheet date

Page 15

Page 16

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 16 Market overview 340B market is maturing 340B Market evolution Potential implications for customers What is to come? This $100 billion program is facing increasing regulatory, operational, and financial complexity, while remaining critical to the healthcare organisations it serves. Draft initiatives being considered, each with varying likelihoods of adoption: • New Rebate Model Pilot HRSA 1/1/27 • SUSTAIN 340B Act (Senate) S.5244 • SECURE 340B Act (House) H.R.9599 • ACCESS 340B Act (House) H.R.5256 • Ongoing Unilateral Manufacturer’s restrictions • State protection of Contract Pharmacies • Centralised clearing house • Legal challenges to 340B & Rebate. • Rebate model pilot expected 1/1/27. • Overall 340B reform expected to be gradual evolution not a big bang. • Hospitals will need to increase evidencing of valid claims and this more complex and auditable workflow drives need for Craneware software solutions. • Revenue pressure on certain of our established 340B products is expected to be supplemented, and over time replaced, by our newly launched Trisus® OneLink – Medication platform. Rebate model • Introduces significant cash flow implications to hospitals. • Creates new, highly complex workflow requirements. Reporting implications: • Tougher compliance, reporting, data and audit requirements. • Proving patient eligibility may become more complex. • Referrals become more complex. Program components • Contract pharmacies would be protected under SUSTAIN & SECURE, restricted under ACCESS. • Rebates would be delayed or disappear under SUSTAIN & SECURE, maintained/extended under ACCESS.

Page 17

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 17 Trisus® OneLink℠ Medication One workflow from eligibility through financial validation Trisus® OneLink℠ Medication One workflow from eligibility through financial validation Trisus® OneLink℠ Medication brings 340B rebates, Maximum Fair Price refunds, and manufacturer and Enhanced Services Platform requirements into one process. Eligibility Submission Tracking Reconciliation Validation Identify applicable activity Coordinate and automate submissions Monitor status Connect results with submitted activity Support financial transparency and auditability Automate Repeatable Work • Eligible claim identification • Automated submission • Conflict detection • Rejection reconciliation Reduce Fragmented Work • Fewer disconnected tools • Less manual reconciliation • One workflow within Trisus Improve Financial Transparency • Submission and refund status • Reconciliation and financial validation • Auditability Initial release: Automated ESP submissions with support for prescription and medical claims. Designed to extend: Additional manufacturers, reporting requirements, and medication pricing frameworks. • A connected medication financial- performance workflow, which can accommodate changing manufacturer, reporting, and pricing requirements. • Brings eligibility, submission, tracking, reconciliation, and validation together, building on trusted Sentinel and Sentrex data rather than creating another disconnected system. • Available via our existing Trisus platform. • Increasing level of enquiries.

Page 18

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 18 Growth Strategy Major increase in embedded Trisus® capabilities and return to Best in KLAS for Trisus Chargemaster Trisus Assist AI-powered assistant streamlines compliance workflows, delivers fast, context-aware guidance and integrates seamlessly into customer processes: • In use across +400 customers Trisus Assist for Trisus Labor & Productivity AI-enhanced demand forecasting and staffing optimisation, embedded within Trisus Labor Productivity – addressing an area of 60% of hospital operating expense: • Launched in H2 FY26 Reimbursement Intelligence AI-powered contract structuring and reimbursement modelling, embedded within Trisus: • Full launch FY27 include an intelligent file ingestion engine, simplifying workflows and supporting multi-facility mapping, which improves data integrity and accelerates implementation.Platform updates:

Page 19

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 19 Growth Strategy A consistent focus on our strengths Evolving market and margin pressure continue to be a driver • Alongside major focus on drug pricing, hospitals still seeing pressure on margins. • Hospital consolidation expected to continue – driving further expansion opportunities, as new hospitals join our customer groups. • Trisus’ powerful ROI across each of our focus areas is a compelling financial proposition. Deepen customer connections & extend reach • Our solutions ability to mitigate the impact on customer cash flow is increasing our relevance to hospital CFOs’ priorities. • Increasingly embedded in core customer workflows. • Microsoft partnership extends our reach, adds sales capacity and supports a growing pipeline. Leverage the power of our data • 340B data now transitioned onto Trisus, providing the opportunity to expand our offerings. • Trisus OneLink Medication: launched. • Revenue integrity product launches to come.

Page 20

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 20 Conclusion & Outlook Strong foundations to deliver growth from FY28 Hospitals need to protect operating margins, without cutting services. Reimbursement complexity and regulatory demands are increasing. Financial reset provides certainty and opportunity to rebuild. We remain a profitable, cash generative, robust business. We have Best in KLAS® offerings which are deeply integrated into core customer workflows and market leading 340B product family. Innovating at pace, combining our data sets, AI and long-standing industry expertise to provide unique insights and actions.

Page 21

Page 22

Page 23

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 23 Major shareholders Shareholder % of Issued Share Capital Keith Neilson (CEO & co-founder) 9.42% Octopus Investments 7.19% Liontrust Asset Management 6.70% Gordon Craig (co-founder) 6.06% Richard Griffiths 4.28% Rathbones 4.13% Canaccord Genuity Group 4.04% BlackRock 3.93% Aegon Asset Management 3.82% Fidelity International 3.58% aberdeen 3.21% Odsyssean Investment Trust 3.01% General Information • Share Price 1300p (at 17/09/2026) • Market AIM • Ticker CRW • Market Cap. £444m • Ord. shares in issue 34.2m • Options Outstanding c. 1m

Page 24

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 24 The Craneware Group Key Strengths Significant Market Need Healthcare Providers face: • Regulatory changes • Rising expectations • Increasing costs Requiring solutions to optimize operational & financial performance. Strong Competitive Position Attractive SaaS Business Model Positive Impact On Society 1 Our independence means: • We only process data to benefit our customers. • We have been trusted to perform this service for over 25 years. • Proof can be shown as we hold operational data for over 200m patient encounters. 2 Our customers enjoy: • Customer voted, award winning products. • Extensive experience driving growth through innovation. • Strong strategic partnerships, enhanced by our solid financial standing and long-term market leadership. 4 Our Customers report: • Annual savings $1.5+bn • Funds reinvested into patient care, enabling focus on excellent clinical services. • Enhanced staff wellbeing due to: • Greater accuracy • Improved efficiency • Decreased errors 5 Extensive Customer Base Our solutions deliver: • Enhanced operational & financial performance. • To over 2,000 healthcare systems, including approximately 12,000 hospitals, clinics, & pharmacies. • Fast deployment on Azure to leverage additional cloud & AI advantages. 3

Page 25

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 25 Evolving 340B market and our approach (Video) Lidia Rodriguez-Hupp Chief Customer Officer Wyley McCoy SVP Medication and Supplies Dave Genovese SVP Customer Success The 340B Market in Transition • 340B is maturing. • 340B is becoming an enterprise financial issue. • Craneware has demonstrated its ability to respond to change. Engineering for What Comes Next • The challenge is expanding beyond traditional 340B workflows. • Trisus OneLink – Medication connects the financial workflow. • Craneware is building for change, not one regulation. Market Update: Spotlight on 340B

Page 26

© 2026 Craneware, Inc. All rights reserved. This document is confidential, is protected by trade secret laws, and may not be copied or disseminated in any form, including electronically. 26 Forward Looking Statements This Report may contain forward-looking statements. Any forward-looking statement has been made by the directors in good faith based on the information available to them up to the time of approval of this Statement and should be treated with caution due to the inherent uncertainties, including both economic and business risk factors, underlying such forward-looking information. To the extent that this Statement contains any statement dealing with any time after the date of its preparation, such statement is merely predictive and speculative as it relates to events and circumstances which are yet to occur and therefore the facts stated and views expressed may change. Craneware undertakes no obligation to update these forward-looking statements.

Slides